AU625623B2 - Herpes virus recombinant poxvirus vaccine - Google Patents

Herpes virus recombinant poxvirus vaccine Download PDF

Info

Publication number
AU625623B2
AU625623B2 AU55520/90A AU5552090A AU625623B2 AU 625623 B2 AU625623 B2 AU 625623B2 AU 55520/90 A AU55520/90 A AU 55520/90A AU 5552090 A AU5552090 A AU 5552090A AU 625623 B2 AU625623 B2 AU 625623B2
Authority
AU
Australia
Prior art keywords
virus
dna
recombinant
poxvirus
herpesvirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU55520/90A
Other languages
English (en)
Other versions
AU5552090A (en
Inventor
Enzo Paoletti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of AU5552090A publication Critical patent/AU5552090A/en
Application granted granted Critical
Publication of AU625623B2 publication Critical patent/AU625623B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU55520/90A 1989-04-17 1990-04-16 Herpes virus recombinant poxvirus vaccine Expired AU625623B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US33900489A 1989-04-17 1989-04-17
US39448889A 1989-08-16 1989-08-16
US502834 1990-04-04
US339004 1990-04-04
US07/502,834 US5338683A (en) 1981-12-24 1990-04-04 Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US394488 1990-04-04

Publications (2)

Publication Number Publication Date
AU5552090A AU5552090A (en) 1990-11-16
AU625623B2 true AU625623B2 (en) 1992-07-16

Family

ID=27407304

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55520/90A Expired AU625623B2 (en) 1989-04-17 1990-04-16 Herpes virus recombinant poxvirus vaccine

Country Status (17)

Country Link
US (3) US5338683A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP3083839B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR920700289A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT405184B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU625623B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE1004369A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2014465C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH682671A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE4090565T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK176464B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2647808B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2246784B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE61098B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1241119B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU88018A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL195016C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1990012882A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5674735A (en) * 1990-07-06 1997-10-07 University Court Of The University Of Glasgow DNA encoding the EHV-4 gH or gC glycoprotein
GB9014950D0 (en) * 1990-07-06 1990-08-29 Univ Glasgow Ehv-4 glycoprotein vaccine
US7374768B1 (en) * 1990-09-25 2008-05-20 Xenova Research Limited Viral vaccines
BR9106879A (pt) * 1990-09-25 1993-07-20 Cantab Pharma Res Virus mutuante nao retroviral,uso do mesmo,vacina e processo de manufaturar umvirus mutante
US5759552A (en) * 1991-03-07 1998-06-02 Virogenetics Corporation Marek's disease virus recombinant poxvirus vaccine
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
EP0561034B1 (en) * 1991-08-26 1999-06-09 IMMUNO Aktiengesellschaft Direct molecular cloning of a modified chordopox virus genome
DE69133333T2 (de) * 1991-08-26 2004-07-29 Baxter Healthcare S.A. Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken
US5869312A (en) * 1992-01-13 1999-02-09 Syntro Corporation Recombinant swinepox virus
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US6136318A (en) * 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
CA2156423A1 (en) * 1993-02-26 1994-09-01 Mark D. Cochran Recombinant fowlpox viruses and uses thereof
US6010703A (en) * 1993-07-26 2000-01-04 Board Of Trustees Operating Michigan State University Recombinant poxvirus vaccine against feline rhinotracheitis
JP3745370B2 (ja) * 1994-03-30 2006-02-15 ヴァイロジェネティクス コーポレイション イヌヘルペスウイルスｇＢ、ｇＣおよびｇＤの、核酸およびアミノ酸配列とその利用
ES2243937T3 (es) * 1994-04-29 2005-12-01 Baxter Healthcare S.A. Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños.
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
US6183752B1 (en) * 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
ATE408011T1 (de) 1998-02-24 2008-09-15 Sisters Of Providence In Orego Zusammensetzungen, die entweder ein ox-40- rezeptor-bindemittel oder eine für ein solches bindemittel kodierende nukleicsäuresequenz enthalten, und verfahren zur verbesserung der antigenspezifischen immunantwort
MXPA00008352A (es) 1998-02-27 2002-10-17 Univ Pennsylvania Vacunas, composiciones inmunoterapeuticas y metodos para usar las mismas.
AU3498200A (en) 1999-02-19 2000-09-04 Michigan State University An antigen test to detect equine protozoal myeloencephalitis in horse serum and cerebrospinal fluid
BR0008645A (pt) 1999-03-03 2002-01-22 Univ Pennsylvania Métodos de induzir uma resposta imunológica contra um imunógeno em um indivìduo, de reduzir rejeição de células, tecido ou órgão doadores nã0-assemelhados em um indivìduo e uma resposta imunológica dominante em um indivìduo e de expandir uma subpopulação de células t associadas com uma resposta imunológica especìfica, plasmìdeo, e, composição
WO2000066162A1 (en) * 1999-04-30 2000-11-09 The Trustees Of The University Of Pennsylvania Mutant human cd80 and compositions for and methods of making and using the same
WO2000077043A2 (fr) * 1999-06-10 2000-12-21 Merial Vaccins adn pour animaux de compagnie et de sport
AU5329300A (en) 1999-06-10 2001-01-02 Michigan State University Feline calicivirus isolated from cat urine and vaccines thereof
US7419668B1 (en) 1999-09-02 2008-09-02 Board Of Trustees Of Michigan State University Vaccine to control equine protozoal myeloencephalitis in horses
EP1207889A4 (en) 1999-09-02 2004-05-19 Univ Michigan State VACCINE FOR COMBATING EQUINE MYELOENCEPHALITIS IN PROTOZOA
JP2003518073A (ja) * 1999-12-21 2003-06-03 メリアル クリプトスポリジウムパルヴァムと他の腸内病原体の抗原を含む組成物およびワクチン
JP2004525604A (ja) * 2000-07-14 2004-08-26 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア Ｈｉｖアクセサリータンパク質をコードするｄｎａワクチン
CA2424216A1 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
IL154712A0 (en) * 2000-11-23 2003-10-31 Bavarian Nordic As Modified vaccinia ankara virus variant
US20020108132A1 (en) * 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
US7176300B2 (en) * 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
US7541512B2 (en) * 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
AU2002255995A1 (en) * 2001-03-30 2002-10-15 Avigenics, Inc. Avian lysozyme promoter
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
US20040037848A1 (en) * 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
AU2002329176A1 (en) 2001-05-25 2002-12-23 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
US7550650B2 (en) * 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US20100333219A1 (en) * 2001-11-30 2010-12-30 Synageva Biopharma Corp. Methods of protein production using ovomucoid regulatory regions
US7294507B2 (en) * 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US7335761B2 (en) * 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
US20040241723A1 (en) * 2002-03-18 2004-12-02 Marquess Foley Leigh Shaw Systems and methods for improving protein and milk production of dairy herds
DE60314823T3 (de) * 2002-04-19 2017-11-16 Bavarian Nordic A/S Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
MXPA04011194A (es) * 2002-05-16 2005-02-14 Bavarian Nordic As Virus de viruela recombinantes que expresan los genes homologos introducidos dentro del genoma viral de la viruela.
AU2003264144C1 (en) * 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
JP2006509526A (ja) * 2002-12-13 2006-03-23 アヴェンティス パストゥール インコーポレイテッド トリ胚性幹細胞上におけるａｌｖａｃの産生
CN1980571A (zh) * 2003-01-24 2007-06-13 阿维季尼克斯股份有限公司 禽类及禽蛋中表达的外源蛋白质
US7262027B2 (en) * 2003-03-14 2007-08-28 Medical College Of Ohio Polypeptide and DNA immunization against Coccidioides spp. infections
EP2390352A1 (en) 2003-03-18 2011-11-30 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
WO2004112706A2 (en) 2003-06-13 2004-12-29 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
ES2417019T3 (es) 2003-11-13 2013-08-05 University Of Georgia Research Foundation, Inc. Procedimiento de caracterización del virus de la enfermedad de la bursitis infecciosa
AU2005244673B2 (en) 2004-02-19 2009-12-10 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
US20080274140A1 (en) * 2004-11-19 2008-11-06 David B Weiner Vaccines and Methods for Using the Same
CA2589460A1 (en) * 2004-11-24 2006-06-01 Theraptosis S.A. New peptides useful as dual caspase-2/-6 inhibitors and their biological applications
ATE461710T1 (de) 2005-04-25 2010-04-15 Merial Ltd Nipah-virus-impfstoffe
CN103550768B (zh) * 2005-07-28 2016-01-20 硕腾服务有限责任公司 疫苗施用方法、新猫杯状病毒、及抗猫细小病毒和猫疱疹病毒的动物免疫方法
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
EP2186823A1 (en) 2005-11-14 2010-05-19 Merial Limited Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7745158B2 (en) * 2005-12-14 2010-06-29 Kimberly-Clark Worldwide, Inc. Detection of secreted aspartyl proteases from Candida species
ATE533782T1 (de) 2006-01-13 2011-12-15 Univ Pennsylvania Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
EP2759307B1 (en) 2006-03-29 2016-11-09 Merial Limited Vaccine against Streptococci
WO2007136763A2 (en) * 2006-05-19 2007-11-29 Sanofi Pasteur, Inc. Immunological composition
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
AU2007278831B2 (en) 2006-07-28 2013-03-21 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
AU2007345347B2 (en) 2007-01-26 2013-11-07 Synageva Biopharma Corp Transgene expression in avians
AU2007352618B2 (en) 2007-05-02 2013-07-18 Boehringer Ingelheim Animal Health USA Inc. DNA plasmids having improved expression and stability
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
US20090246226A1 (en) * 2008-03-28 2009-10-01 Zeon Corporation Avian vaccines possessing a positive marker gene
CA2720166A1 (en) * 2008-04-04 2009-10-08 David B. Weiner Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
CN102016023A (zh) 2008-04-04 2011-04-13 宾夕法尼亚州立大学托管会 使用il-28和组合物的疫苗和免疫治疗及其使用方法
EP2283035B1 (en) 2008-05-08 2015-07-29 Merial Limited Leishmania vaccine using sand fly salivary immunogen
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
WO2010050939A1 (en) 2008-10-29 2010-05-06 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
CA2653478A1 (en) 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
US9050287B2 (en) 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
US20100192236A1 (en) * 2009-01-28 2010-07-29 University Of South Carolina Modulation of Delta Opioid Receptor Expression
CN103585643A (zh) 2009-04-03 2014-02-19 梅里亚有限公司 运载新城疫病毒的禽疫苗
US20100284977A1 (en) * 2009-04-28 2010-11-11 University Of South Carolina Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters
US9670506B2 (en) 2009-04-30 2017-06-06 Consejo Superior De Investigaciones Cientificas Modified immunization vectors
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
AU2010291900A1 (en) 2009-09-14 2012-03-22 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
WO2011054011A2 (en) 2009-11-02 2011-05-05 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
WO2011097640A1 (en) 2010-02-08 2011-08-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
US8986706B2 (en) 2010-08-31 2015-03-24 Merial, Inc. Newcastle disease virus vectored herpesvirus vaccines
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
US8927692B2 (en) 2010-11-12 2015-01-06 The Trustees Of The University Of Pennsylvania Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
CN103827131B (zh) 2011-01-31 2017-06-30 宾夕法尼亚大学托管会 编码新型疱疹抗原的核酸分子、包含所述核酸分子的疫苗及其使用方法
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
CN103442732B (zh) 2011-02-11 2017-04-12 宾夕法尼亚大学托管会 编码乙型肝炎病毒核心蛋白的核酸分子和包含其的疫苗
AU2012240246A1 (en) 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
WO2012138783A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
WO2012145577A1 (en) 2011-04-20 2012-10-26 Merial Limited Adjuvanted rabies vaccine with improved viscosity profile
CA2834288A1 (en) 2011-04-25 2012-11-01 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
EP2714077B1 (en) 2011-06-01 2018-02-28 Merial, Inc. Needle-free administration of prrsv vaccines
KR102071228B1 (ko) 2011-07-11 2020-01-30 이노비오 파마수티컬즈, 인크. 교차-보호성 아레나바이러스 백신 및 이의 사용 방법
AU2012284558B2 (en) 2011-07-20 2017-06-29 Centre National De La Recherche Scientifique Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
WO2013025274A1 (en) 2011-08-12 2013-02-21 Merial Limited Vacuum -assisted preservation of biological products, in particular of vaccines
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
KR102373828B1 (ko) 2011-10-12 2022-03-14 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 인간 파필로마 바이러스에 대한 백신 및 이것을 사용하는 방법
KR101679731B1 (ko) 2011-10-24 2016-11-25 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 hcv 백신 및 이것을 사용하는 방법
KR20240096837A (ko) 2011-12-12 2024-06-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
WO2013090294A1 (en) 2011-12-12 2013-06-20 The Trustees Of The University Of Pennsylvania Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
HK1201205A1 (en) * 2012-03-20 2015-08-28 Merial, Inc. Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
EP3511337A1 (en) 2012-04-10 2019-07-17 The Trustees of The University of Pennsylvania Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same
MX360137B (es) 2013-02-21 2018-10-24 Boehringer Ingelheim Vetmedica Gmbh Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
WO2014164697A1 (en) 2013-03-12 2014-10-09 Merial Limited Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
CN114181961A (zh) 2013-03-12 2022-03-15 宾夕法尼亚大学理事会 用于人乳头状瘤病毒的改进疫苗及其使用方法
WO2014145951A2 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
EP3607974A1 (en) 2013-03-15 2020-02-12 The Trustees of The University of Pennsylvania Cancer vaccines and methods of treatment using the same
EP3125932A1 (en) 2014-04-03 2017-02-08 Boehringer Ingelheim Vetmedica, Inc. Porcine epidemic diarrhea virus vaccine
US10010499B2 (en) 2014-11-03 2018-07-03 Merial Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
PH12017502380B1 (en) 2015-06-23 2022-10-26 Merial Inc Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
KR20180042167A (ko) 2015-08-31 2018-04-25 베링거잉겔하임베트메디카게엠베하 선천성 진전을 위한 페스티바이러스 백신
US20170072042A1 (en) 2015-09-16 2017-03-16 Boehringer Ingelheim Vetmedica, Inc. Salmonella choleraesuis-salmonella typhimurium vaccines
EP3515504B1 (en) 2016-09-20 2023-07-12 Boehringer Ingelheim Vetmedica GmbH Canine adenovirus vectors
BR112019005516A2 (pt) 2016-09-20 2019-06-18 Boehringer Ingelheim Vetmedica Gmbh novo sítio de inserção do ehv orf70
BR112019005415A2 (pt) 2016-09-20 2019-10-22 Boehringer Ingelheim Vetmedica Gmbh nova vacina contra influenza suína
US11261464B2 (en) 2016-09-20 2022-03-01 Boehringer Ingelheim Vetmedica Gmbh Promoters
US10660952B2 (en) 2016-11-03 2020-05-26 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
US10485866B2 (en) 2016-11-03 2019-11-26 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus
US12150983B2 (en) 2017-01-30 2024-11-26 Boehringer Ingelheim Animal Health USA Inc. Porcine coronavirus vaccines
BR112020000711A2 (pt) 2017-07-12 2020-07-14 Boehringer Ingelheim Animal Health USA Inc. composições imunogênicas de senecavírus a e métodos destas
MX2020003071A (es) 2017-09-23 2020-07-28 Boehringer Ingelheim Vetmedica Gmbh Sistema de expresion de paramyxoviridae.
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
CA3204873A1 (en) 2017-12-13 2019-06-20 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting muc16 and uses thereof
EP3723810A4 (en) 2017-12-13 2022-02-23 Inovio Pharmaceuticals, Inc. CANCER VACCINES TARGETING MESOTHELIN AND THEIR USES
KR20250016461A (ko) 2017-12-13 2025-02-03 이노비오 파마수티컬즈, 인크. Prame를 표적으로 하는 암 백신 및 이의 용도
AU2018383663B2 (en) 2017-12-13 2023-12-21 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting BORIS and uses thereof
RU2711907C2 (ru) * 2017-12-22 2020-01-23 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Рекомбинантный белок, содержащий антигенно-значимые фрагменты белков вируса гепатита Е, используемый в тест-системах для серодиагностики гепатита Е (варианты)
CN111712575B (zh) 2018-02-23 2024-07-19 勃林格殷格翰动物保健有限公司 表达外源猫副粘病毒基因的重组病毒载体系统及由其制备的疫苗
AU2019239552A1 (en) 2018-03-19 2020-09-10 Boehringer Ingelheim Vetmedica Gmbh EHV insertion site UL43
JP7273840B2 (ja) 2018-03-19 2023-05-15 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 不活性化ｕｌ１８および／またはｕｌ８を有する新しいｅｈｖ
CN112088013B (zh) 2018-03-26 2024-12-06 勃林格殷格翰动物保健美国有限公司 制备免疫原性组合物的方法
EP3852800A1 (en) 2018-09-20 2021-07-28 Boehringer Ingelheim Vetmedica GmbH Intranasal vector vaccine against porcine epidemic diarrhea
US11464852B2 (en) 2018-09-20 2022-10-11 Boehringer Ingelheim Vetmedica Gmbh Modified PEDV spike protein
CN115768784A (zh) 2020-02-06 2023-03-07 勃林格殷格翰动物保健有限公司 用于检测抗弹状病毒抗体的多肽
WO2022076979A1 (en) 2020-10-05 2022-04-14 Boehringer Ingelheim Vetmedica Gmbh Fusion protein useful for vaccination against rotavirus
WO2022076977A1 (en) 2020-10-05 2022-04-14 Boehringer Ingelheim Animal Health USA Inc. Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
US20240050555A1 (en) 2022-04-05 2024-02-15 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for vaccination against rotavirus
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1061898A (en) 1963-03-07 1967-03-15 Philips Electronic Pharma Method for protecting dogs against canine distemper
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
JPH0795954B2 (ja) * 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
EP0162738A1 (en) 1984-04-09 1985-11-27 MOLECULAR GENETICS RESEARCH & DEVELOPMENT LIMITED PARTNERSHIP Production of pseudorabies virus subunit vaccines
EP0261940A3 (en) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies vaccines and dna vectors for recombination with pox viruses
US5242829A (en) * 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
EP0284416B1 (en) * 1987-03-27 1995-02-22 Nippon Zeon Co., Ltd. Recombinant avipoxyvirus
EP0297924A3 (en) * 1987-07-01 1990-07-11 City Of Hope Recombinant vaccinia virus expressing hsv 1 gb
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
WO1990001546A1 (en) * 1988-08-05 1990-02-22 Applied Biotechnology, Inc. Equine herpesvirus-1 vaccine
IE68404B1 (en) 1990-11-20 1996-06-12 Virogenetics Corp Measles virus recombinant poxvirus vaccine

Also Published As

Publication number Publication date
IT1241119B (it) 1993-12-29
LU88018A1 (fr) 1992-03-11
AU5552090A (en) 1990-11-16
FR2647808A1 (fr) 1990-12-07
GB9120655D0 (en) 1991-11-27
DK176464B1 (da) 2008-03-31
GB2246784B (en) 1993-04-28
NL9020677A (nl) 1992-02-03
JP2000157292A (ja) 2000-06-13
IT9020063A0 (it) 1990-04-17
US5482713A (en) 1996-01-09
JP3083839B2 (ja) 2000-09-04
WO1990012882A1 (en) 1990-11-01
JPH04505248A (ja) 1992-09-17
US5338683A (en) 1994-08-16
KR920700289A (ko) 1992-02-19
DK174391A (da) 1991-12-12
AT405184B (de) 1999-06-25
CH682671A5 (fr) 1993-10-29
DE4090565T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-05-14
DE4090565C2 (de) 2000-03-09
DK174391D0 (da) 1991-10-15
BE1004369A5 (fr) 1992-11-10
JP3246735B2 (ja) 2002-01-15
NL195016C (nl) 2003-06-10
CA2014465A1 (en) 1990-10-17
IT9020063A1 (it) 1991-10-17
CA2014465C (en) 1999-06-15
IE901380L (en) 1990-10-17
FR2647808B1 (fr) 1995-03-03
IE61098B1 (en) 1994-09-21
GB2246784A (en) 1992-02-12
ATA902590A (de) 1998-10-15
US6183750B1 (en) 2001-02-06

Similar Documents

Publication Publication Date Title
AU625623B2 (en) Herpes virus recombinant poxvirus vaccine
US5494807A (en) NYVAC vaccinia virus recombinants comprising heterologous inserts
LU88000A1 (fr) Systeme de selection d'hotes de poxvirus du recombinaision
US5688920A (en) Nucleotide and amino acid sequences for canine herpesvirus GB, GC and GD and uses therefor
Guo et al. Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity
US6605465B1 (en) Methods for avoiding maternal immunity
CA2182888C (en) Nucleotide and amino acid sequences of canine herpesvirus gb, gc and gd and uses therefor
CA2259047C (en) Innoculation kits for avoiding maternal immunity
NL195086C (nl) Herpesvirus recombinant pokkenvirus.
AU701599B2 (en) TROVAC fowlpox virus recombinants comprising heterologous inserts